Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Autor: Overton, Edgar T *, Richmond, Gary, Rizzardini, Giuliano, Jaeger, Hans, Orrell, Catherine, Nagimova, Firaya, Bredeek, Fritz, García Deltoro, Miguel, Swindells, Susan, Andrade-Villanueva, Jaime Federico, Wong, Alexander, Khuong-Josses, Marie-Aude, Van Solingen-Ristea, Rodica, van Eygen, Veerle, Crauwels, Herta, Ford, Susan, Talarico, Christine, Benn, Paul, Wang, Yuanyuan, Hudson, Krischan J, Chounta, Vasiliki, Cutrell, Amy, Patel, Parul, Shaefer, Mark, Margolis, David A, Smith, Kimberly Y, Vanveggel, Simon, Spreen, William
Zdroj: In The Lancet 19 December 2020-1 January 2021 396(10267):1994-2005
Databáze: ScienceDirect